The Darzalex Faspro market report provides a comprehensive analysis of market size, growth potential, and segmentation, covering major regions and countries. Key factors driving growth include rising ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients. It has already been submitted for approval in the EU.